Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Zhang Y, Rumgay H, Li M, Cao S, Chen W (2023) Nasopharyngeal Cancer incidence and mortality in 185 countries in 2020 and the projected Burden in 2040: Population-based global epidemiological profiling. JMIR Public Health Surveill 9:e49968

Article  PubMed  PubMed Central  Google Scholar 

Fangzheng W, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S et al (2017) Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma. Oncotarget 8:91150–91161

Article  PubMed  PubMed Central  Google Scholar 

Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17:1509–1520

Article  CAS  PubMed  Google Scholar 

Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27:242–249

Article  CAS  PubMed  Google Scholar 

Wang F, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S et al (2020) Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma. Med (Baltim) 99:e22283

Article  CAS  Google Scholar 

Lee AW, Ng WT, Chan YH, Sze H, Chan C, Lam TH (2012) The battle against nasopharyngeal cancer. Radiother Oncol 104:272–278

Article  PubMed  Google Scholar 

Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L et al (2013) Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 31:2861–2869

Article  CAS  PubMed  Google Scholar 

Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J et al (2021) Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study. J Clin Oncol 39:3273–3282

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 388:1883–1892

Article  CAS  PubMed  Google Scholar 

Zhou H, Lu T, Guo Q, Chen Y, Chen M, Chen Y et al (2020) Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma. Cancer Med 9:2732–2741

Article  CAS  PubMed  PubMed Central  Google Scholar 

Twu CW, Lin PJ, Tsou HH, Liu YC, Jiang RS, Liang KL et al (2022) Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma. Head Neck 44:1453–1461

Article  PubMed  Google Scholar 

Sun XS, Liu SL, Liang YJ, Chen QY, Li XY, Tang LQ et al (2020) The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: a propensity score matching study. Cancer Commun 40:32–42

Article  CAS  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR et al (2012) A phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncology: Cancer Clin Trials 35:255–260

Article  CAS  Google Scholar 

Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF et al (2022) Effect of Capecitabine maintenance Therapy Plus Best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal Carcinoma who had received induction chemotherapy: a phase 3 Randomized Clinical Trial. JAMA Oncol 8:553–561

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Huang H, Yang H, Hu X, Liu M, Huang C et al (2023) Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study. J Cancer Res Clin Oncol 149:4327–4338

Article  CAS  PubMed  Google Scholar 

Han J, Lan X, Tian K, Shen X, He J, Chen N (2022) Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma. Front Public Health 10:1086393

Article  PubMed  Google Scholar